Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 1.1 million
▲ 5% vs 2024
Profit
Caution€ -5 million
▼ 30% vs 2024
Debts
Low€ 2.1 million
▼ 4% vs 2024
Protealis from Gent, company number BE0765251410, closed financial year 2025 with a result of € -5 million after tax. For that financial year Protealis recorded a gross margin of € 1.1 million and equity of € 9.1 million. Compared with financial year 2024, the result moved from € -3.8 million to € -5 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
What happened at Protealis?
What happened at Protealis in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- DE LIER stepped down as director. NBB
- KORYS MANAGEMENT stepped down as director. NBB
- Hartmut VAN LENGERICH stepped down as director. NBB
- Tom VIAENE stepped down as director. NBB
- Willem BROEKAERT stepped down as director. NBB
- Innovation Industries Fund II Coöperatief U.A. stepped down as director. NBB
- Patrik HAESEN stepped down as director. NBB
- AMPHIBEAN BV stepped down as director. NBB
In short
From € 3.9 million loss in 2022 to € 5 million loss in 2025.
On average € 62,800 of value added per employee in 2025.
A new publication or filing at Protealis? We notify you, reason included.
Follow ProtealisNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by François VAN LIERDE
Also active at: ACKERMANS & VAN HAAREN, APIX Biosciences
since 2024 · until 2030
Tom VIAENE
Director
since 2026 · until 2028
Willem BROEKAERT
Director
since 2021 · until 2027
Director · represented by Vincent DE SMET
Also active at: Colruyt Group, GINSTBRONNEN, reMYND +24 more
since 2024 · until 2029
Johan CARDOEN
Director
since 2022 · until 2025
Hartmut VAN LENGERICH
Director
since 2024 · until 2029
Innovation Industries Fund II Coöperatief U.A.
Director · represented by Douwe GREEBE CAAJ
since 2021 · until 2027
Patrik HAESEN
Director
since 2021 · until 2027
Director · represented by Benjamin Laga
since 2021 · until 2027
David Buckeridge Investigations Limited
Director · represented by David Buckeridge
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 94
9052 Gent
Legen Heirweg 20 box D
9890 Gavere
Active since 10 December 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
BioLyo Technologies
€ 1 million gross margin · 2024
Zomagen Biosciences Belgium
€ 1.2 million gross margin · 2025
AnimAb
€ 28,596 gross margin · 2025
ExeVir Bio
€ -1.2 million gross margin · 2025
YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY
+1 more
Details
- Company number
- 0765.251.410
- VAT number
- BE 0765.251.410
- Registered office
- Technologiepark-Zwijnaarde 94, 9052 Gent
- Names & denominations
- Protealis
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 March 2021
- Peppol
- Active · Active since 30 Apr 2021
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied